var data={"title":"Rivaroxaban: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rivaroxaban: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/366850?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rivaroxaban-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rivaroxaban: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13135512\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Premature discontinuation increases the risk of thrombotic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Premature discontinuation of any oral anticoagulant, including rivaroxaban, increases the risk of thrombotic events. If anticoagulation with rivaroxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematomas:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas have occurred in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; or a history of spinal deformity or spinal surgery. The optimal timing between the administration of rivaroxaban and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the benefits and risks before neuraxial intervention in patients who are anticoagulated or are to be anticoagulated for thromboprophylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13107816\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xarelto;</li>\n      <li>Xarelto Starter Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724104\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Xarelto</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724108\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Factor Xa Inhibitor;</li>\n      <li>\n        Direct Oral Anticoagulant (DOAC)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724168\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Extremes of body weight (&lt;50 kg or &gt;120 kg) do not significantly influence rivaroxaban exposure (Kubitza 2007). However, The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of rivaroxaban (and other direct oral anticoagulants) in patients with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg due to the lack of clinical data in this population (ISTH [Martin 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis (DVT), pulmonary embolism (PE) treatment:</b> Oral: Initial: 15 mg twice daily with food for 21 days followed by 20 mg once daily with food. <b>Note:</b> LMWH is preferred over oral anticoagulation for treatment of patients <i>with</i> cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences; however, ACCP guidelines recommend the following:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Long-term (first 3 months): </i>3 months is the minimum duration for most patients <i>without</i> cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended therapy (after first 3 months and no scheduled stop date):</i> May be considered in patients with unprovoked first DVT of the leg or PE who do not have a high bleeding risk. Extended therapy is recommended in patients with unprovoked second DVT of the leg or PE who do not have a high risk of bleeding. In patients <i>with</i> cancer, extended therapy is recommended, although high bleeding risk confers a lower grade of recommendation. All patients receiving extended therapy should be reassessed at periodic intervals for continuing use of therapy (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reduction in the risk (secondary prevention) of recurrent DVT/PE after at least 6 months of initial anticoagulant treatment:</b> Oral: 10 mg once daily. <b>Note:</b> Duration of treatment in the EINSTEIN-Extension Study and the EINSTEIN CHOICE trial was 6 to 12 months in addition to the initial anticoagulant treatment duration of 6 to 12 months (EINSTEIN Investigators 2010; EINSTEIN CHOICE [Weitz 2017]). For patients who have an unequivocal indication for long-term anticoagulation, reduced-intensity dosing (ie, 10 mg once daily) has not been evaluated (Crowther 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative DVT thromboprophylaxis:</b> Oral: <b>Note:</b> Initiate therapy after hemostasis has been established, 6 to 10 hours postoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Knee replacement: 10 mg once daily; recommended total duration of therapy: 12 days; ACCP recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hip replacement: 10 mg once daily; total duration of therapy: 35 days; ACCP recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b> Oral: 20 mg once daily with the evening meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Superficial vein thrombosis, acute symptomatic</b> <b>(off-label use): </b>Oral: 10 mg once daily for 45 days (Beyer-Westendorf 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion from one anticoagulant to another:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>from</i> warfarin: Discontinue warfarin and initiate rivaroxaban as soon as INR falls to &lt;3.0 (US labeling) or &le;2.5 (Canadian labeling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>to</i> warfarin: <b>Note:</b> Rivaroxaban affects INR; therefore, initial INR measurements after initiating warfarin may be unreliable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">US labeling: Discontinue rivaroxaban and initiate both warfarin and a parenteral anticoagulant at the time the next dose of rivaroxaban would have been taken (other approaches to this conversion may be acceptable).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling: Continue rivaroxaban concomitantly with warfarin until INR &ge;2.0 and then discontinue rivaroxaban. <b>Note:</b> Caution must be employed with this strategy given the lack of an antidote for rivaroxaban reversal. During the first 2 days of concomitant therapy, usual doses of warfarin may be given without INR testing. Thereafter, while on concomitant therapy, measure INR daily just prior to the next scheduled rivaroxaban dose, as appropriate. After rivaroxaban has been discontinued, INR testing may be done at least 24 hours after the last rivaroxaban dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>from </i>continuous infusion unfractionated heparin: Initiate rivaroxaban at the time of heparin discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>to</i> continuous infusion unfractionated heparin: Discontinue rivaroxaban and initiate continuous infusion unfractionated heparin at the time the next dose of rivaroxaban would have been taken.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>from</i> anticoagulants (other than warfarin and continuous infusion unfractionated heparin):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">US labeling: Discontinue current anticoagulant and initiate rivaroxaban &le;2 hours prior to the next regularly scheduled evening dose of the discontinued anticoagulant.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling: Discontinue current anticoagulant and initiate rivaroxaban &le;2 hours prior to the next regularly scheduled evening dose of the discontinued anticoagulant; patients previously receiving prophylactic doses of anticoagulant may initiate rivaroxaban &ge;6 hours after last prophylactic dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion <i>to</i> other anticoagulants (other than warfarin): Discontinue rivaroxaban and initiate the anticoagulant at the time the next dose of rivaroxaban would have been taken.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724169\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In older adults with CrCl between 30 to 50 mL/minute, reduce dose (specific dosage adjustment not provided). In older adults with CrCl &lt;30 mL/minute, avoid use due to increased risk of bleeding (Beers Criteria [AGS 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724170\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Clinical trials evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (weight range of patients enrolled in clinical trials: 33 to 209 kg) (data on file; Janssen Pharmaceuticals Inc 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT, PE, reduction of the risk of recurrent DVT/PE:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary. The Beers Criteria recommends to reduce the dose in older adults &ge;65 years with a CrCl between 30 to 50 mL/minute (specific dosage adjustment not provided) (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 50 mL/minute: 15 mg once daily with the evening meal; assess renal function as clinically indicated and adjust dose accordingly; discontinue use in patients who develop acute renal failure. Some recommend to avoid use in patients with CrCl &lt;30 mL/minute<b> (Xarelto Canadian product labeling 2015). </b>According to the AHA/ACC/HRS, may consider dose reduction in patients with moderate to severe chronic kidney disease (CKD), although safety and efficacy of this approach has not been established (AHA/ACC/HRS [January 2014]). The Beers Criteria recommends to reduce the dose in older adults &ge;65 years with a CrCl between 30 to 50 mL/minute (specific dosage adjustment not provided) and avoiding use if CrCl is &lt;30 mL/minute (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; discontinue use in patients who develop acute renal failure. Some recommend to avoid use in patients with CrCl &lt;30 mL/minute (Xarelto Canadian product labeling 2015). <b>Note:</b> In patients with severe or end-stage chronic kidney disease, warfarin remains the anticoagulant of choice (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative thromboprophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: No dosage adjustment necessary; use with caution and monitor for any signs or symptoms of bleeding. Discontinue use in patients who develop acute renal failure. The Beers Criteria recommends to reduce the dose in older adults &ge;65 years with a CrCl between 30 to 50 mL/minute (specific dosage adjustment not provided) (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>ESRD requiring hemodialysis:</b> Not dialyzable. There are no dosage adjustments provided in the manufacturer's labeling for any indication. Of note, a single dose study using a 15 mg dose in patients with ESRD requiring hemodialysis resulted in similar exposure to those previously studied who had CrCl 15 to 49 mL/minute (Dias 2016; Kubitza 2010). In addition, a single dose and limited (7 day) multiple daily dose study using 10 mg demonstrated similar exposure seen in healthy volunteers receiving 20 mg and no accumulation was seen after multiple daily dosing (DeVries 2015). <b>Note:</b> Clinical efficacy and long-term safety studies have not been performed in this population; therefore, if used, do so with extreme caution while closely monitoring for bleeding. Others do not recommend use in these patients (Chan 2016). In patients with severe or end-stage chronic kidney disease, warfarin remains the anticoagulant of choice (AHA/ACC/HRS [January 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724171\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Limited data indicates pharmacokinetics and pharmacodynamic response were similar to healthy subjects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (Child-Pugh class B or C) and any hepatic disease associated with coagulopathy: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild hepatic impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling. Limited data indicate pharmacokinetics and pharmacodynamic response were similar to healthy subjects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (Child-Pugh class B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Limited data indicate a significant increase in pharmacodynamic response and pharmacokinetics (eg, increased AUC [~2.3-fold for total and ~2.6-fold for unbound] and C<sub>max</sub> [27% for total and 38% for unbound]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment (including Child-Pugh class B and C) associated with coagulopathy, and having clinically relevant bleeding risk: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330599\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Body weight &gt;120 kg did not significantly influence rivaroxaban exposure (Kubitza 2007). Clinical outcomes in postoperative thromboprophylaxis trials were also not affected by weight (up to 190 kg) (Turpie 2011). Therefore, dosage adjustment may not be required. The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of rivaroxaban (and other direct oral anticoagulants) in patients with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg due to the lack of clinical data in this population. If used in a patient with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, ISTH suggests measuring peak and trough levels using an antifactor Xa assay or mass spectrometry. If drug level is below the expected range, ISTH suggests changing to a vitamin K antagonist rather than adjusting the dose of rivaroxaban (ISTH [Martin 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13107817\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xarelto: 10 mg, 15 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xarelto Starter Pack: 15 mg (42s) and 20 mg (9s) (51 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452764\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13376301\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68lubwv/ew/NMJYJJAGgvl+Q==&amp;TOPIC_ID=9498\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724172\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer doses &ge;15 mg with food; dose of 10 mg may be administered without regard to meals. For nonvalvular atrial fibrillation, administer with the evening meal. For patients who cannot swallow whole tablets, the tablets (all strengths) may be crushed and mixed with applesauce immediately prior to use; immediately follow administration of the 15 mg and 20 mg tablets with food (10 mg tablets may be administered without regards to food).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For nasogastric/gastric feeding tube administration, the tablets (all strengths) may be crushed and mixed in 50 mL of water; administer the suspension within 4 hours of preparation and follow administration of the 15 mg and 20 mg tablets immediately with enteral feeding (10 mg tablets may be administered without regards to food). Avoid administration distal to the stomach; a decrease in the AUC and C<sub>max</sub> (29% and 56%, respectively) was observed when rivaroxaban was delivered to the proximal small intestine; further decreases may be seen with delivery to the distal small intestine or ascending colon.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Missed doses: Patients receiving 15 mg twice daily dosing who miss a dose should take a dose immediately to ensure 30 mg of rivaroxaban is administered per day (two 15 mg tablets may be taken together); resume therapy the following day as previously taken. Patients receiving once-daily dosing who miss a dose should take a dose as soon as possible on the same day; resume therapy the following day as previously taken.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724109\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis prophylaxis:</b> Postoperative thromboprophylaxis of deep vein thrombosis (DVT) which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis or pulmonary embolism, treatment:</b> Treatment of DVT or PE. <b>Note: </b>The American College of Chest Physicians (ACCP) guidelines for VTE suggest rivaroxaban (or dabigatran, apixaban, or edoxaban) over a vitamin K antagonist as long-term anticoagulant therapy in patients with DVT of the leg or PE <b>and</b> without cancer (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation:</b> Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for the management of AF recommend oral anticoagulation for patients with nonvalvular AF or atrial flutter with prior stroke, TIA, or a CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge;2. As an alternative to warfarin, rivaroxaban may also be used for at least 3 weeks prior and 4 weeks after cardioversion in patients with AF or atrial flutter of &ge;48 hours duration or when the duration is unknown (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reduction in the risk (secondary prevention) of recurrent deep vein thrombosis and/or pulmonary embolism:</b> Reduction in the risk of recurrence of DVT and pulmonary embolism in patients at continued risk of DVT and PE following at least 6 months of initial anticoagulant treatment for DVT and/or pulmonary embolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50324307\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Recurrent stroke/Transient ischemic attacks (prevention); Superficial vein thrombosis, acute symptomatic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14199109\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724117\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (any bleeding: 5% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (2%), insomnia (2%), anxiety (1%), depression (1%), fatigue (1%), syncope (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Wound secretion (3%), pruritus (2%), skin blister (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (3%), dyspepsia (1%), toothache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Major hemorrhage (&le;1%)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Hepatic: Increased serum transaminases (&gt;3 x ULN: 2% [Watkins 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (3%), limb pain (2%), osteoarthritis (2%), muscle spasm (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (1%), sinusitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylactic shock, anaphylaxis, angioedema, cerebral hemorrhage, cholestasis, epidural hematoma, gastrointestinal hemorrhage, hemiparesis, hemophthalmos, hepatitis, hepatic injury (Liakoni 2014), hypersensitivity reaction, intra-articular bleeding, intracranial hemorrhage, jaundice, retroperitoneal hemorrhage, Stevens-Johnson syndrome, subdural hematoma, thrombocytopenia (&lt;100,000/mm<sup>3</sup> or &lt;50% baseline)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724113\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity to rivaroxaban or any component of the formulation; active pathological bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hepatic disease (including Child-Pugh classes B and C) associated with coagulopathy and clinically relevant bleeding risk; lesions or conditions at increased risk of clinically significant bleeding (eg, hemorrhagic or ischemic cerebral infarction, spontaneous or acquired impairment of hemostasis, active peptic ulcer disease with recent bleeding); concomitant systemic treatment with strong CYP3A4 and P-glycoprotein (P-gp) inhibitors (eg, ketoconazole, itraconazole, posaconazole, ritonavir); concomitant use with any other anticoagulant including unfractionated heparin (except at doses used to maintain central venous or arterial catheter patency), low molecular weight heparins (eg, enoxaparin, dalteparin) or heparin derivatives (eg, fondaparinux); concomitant use with warfarin, dabigatran, or apixaban except when switching therapy to or from rivaroxaban; pregnancy; lactation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724114\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: The most common complication is bleeding; major hemorrhages (eg, intracranial, GI, retinal, epidural hematoma, adrenal bleeding) have been reported. Certain patients are at increased risk of bleeding; risk factors include bacterial endocarditis, congenital or acquired bleeding disorders, vascular retinopathy, thrombocytopenia, recent puncture of large vessels or organ biopsy, stroke, intracerebral surgery, or other neuraxial procedure, severe uncontrolled hypertension, renal impairment, recent major surgery, recent major bleeding (intracranial, GI, intraocular, or pulmonary), concomitant use of drugs that affect hemostasis, and advanced age. Monitor for signs and symptoms of bleeding (weakness, dizziness, unexplained edema). Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin or blood pressure. No specific antidote for rivaroxaban reversal exists. Rivaroxaban is highly protein-bound, therefore, hemodialysis is ineffective. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. Depending on the bleeding severity, activated oral charcoal should be considered if ingestion occurred within 1 to 2 hours of presentation. The following alternative options may also be considered depending on specific clinical scenario: 4-factor unactivated prothrombin concentrate (PCC) (eg, Kcentra) or 4-factor activated prothrombin complex concentrate (aPCC) (eg, FEIBA). Some studies and case reports have shown moderate success in correcting coagulation tests with some of these agents; however, correction of coagulation tests does not imply reversal of the anticoagulation effect of the medication (AHA/ASA [Hemphill 2015; EHRA [Heidbuchel 2015]; NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: As with any oral anticoagulant in the absence of adequate alternative anticoagulation, an increased risk of thrombotic events (including stroke) may occur with premature discontinuation of rivaroxaban. Consider the addition of alternative anticoagulant therapy when discontinuing rivaroxaban for reasons other than pathological bleeding or completion of a course of therapy.</b> An increased rate of stroke was observed during the transition from rivaroxaban to warfarin in clinical trials in atrial fibrillation patients. In a post-hoc analysis of the ROCKET AF trial, patients who temporarily (&gt;3 days) or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban as compared to warfarin (Patel 2013). In patients with non-valvular atrial fibrillation who had an acute ischemic stroke while receiving a DOAC (eg, rivaroxaban), guidelines generally support withholding oral anticoagulation until 4 to 14 days after the onset of neurological symptoms (time frame may vary with shorter times for transient ischemic attack or small, non-disabling stroke and longer times for moderate-to-severe stroke) (AHA/ASA [Kernan 2014]; AHA/ASA [Powers 2018]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh classes B and C) or in patients with any hepatic disease associated with coagulopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate renal impairment (CrCl 30 to 50 mL/minute) when used for postoperative thromboprophylaxis, including patients receiving concomitant drug therapy that may increase rivaroxaban systemic exposure and those with deteriorating renal function. Monitor for any signs or symptoms of blood loss. Discontinue use in patients who develop acute renal failure. Use is not recommended in patients with ESRD requiring hemodialysis (Chan 2016). Avoid use in patients with CrCl &lt;30 mL/minute in DVT/PE and postoperative thromboprophylaxis (rivaroxaban exposure expected to increase). According to the AHA/ACC/HRS, may consider dose reduction in patients with nonvalvular AF and moderate to severe chronic kidney disease (CKD), although safety and efficacy of this approach has not been established; rivaroxaban is not recommended for patients with AF and end-stage CKD or on hemodialysis (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valvular disease: Safety and efficacy have not been established in patients with prosthetic heart valves or significant rheumatic heart disease (eg, mitral stenosis); use is not recommended. Non-valvular atrial fibrillation is defined as atrial fibrillation that occurs in the absence of rheumatic mitral valve disease, mitral valve repair, or prosthetic heart valve (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly. Elderly patients exhibit higher rivaroxaban concentrations compared to younger patients due primarily to reduced clearance. Overall, efficacy of rivaroxaban in the elderly (age &ge;65 years) was similar to that of patients &lt;65 years of age. Both thrombotic and bleeding events were higher in the elderly; however, the risk to benefit profile was favorable among all age groups.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose intolerance: May contains lactose; use is not recommended in patients with lactose or galactose intolerance (eg, Lapp lactase deficiency, glucose-galactose malabsorption).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute pulmonary embolism: Rivaroxaban is <b>not</b> recommended as an alternative to unfractionated heparin in the treatment of acute pulmonary embolism in hemodynamically unstable patients or patients requiring thrombolysis or pulmonary embolectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal or epidural hematoma: <b>[US Boxed Warning]: Spinal or epidural hematomas may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients who are anticoagulated; may result in long-term or permanent paralysis. The risk of spinal/epidural hematoma is increased with the use of indwelling epidural catheters, concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, or a history of spinal deformity or spinal surgery. Monitor for signs of neurologic impairment (eg, midline back pain, numbness/weakness of legs, bowel/bladder dysfunction); prompt diagnosis and treatment are necessary. In patients who are anticoagulated or pharmacologic thromboprophylaxis is anticipated, assess risks versus benefits prior to neuraxial interventions. The optimal timing between the administration of rivaroxaban and neuraxial procedures is not known.</b> Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low. European guidelines recommend waiting at least 22 to 26 hours following the last rivaroxaban dose when using prophylactic dosing (eg, 10 mg once daily) before catheter placement or lumbar puncture (Gogarten 2010). When higher doses are used (eg, 20 mg once daily), some suggest avoidance of neuraxial procedures for at least 48 hours (Rosencher 2013). In patients who have received neuraxial anesthesia concurrently with rivaroxaban (usually in patients undergoing knee or hip replacement surgery), avoid removal of epidural catheter for at least 18 hours following the last rivaroxaban dose; avoid rivaroxaban administration for at least 6 hours following epidural catheter removal; if traumatic puncture occurs, avoid rivaroxaban administration for at least 24 hours. In addition to these and other clinical variables, consider renal function and the age of the patient (elderly patients exhibit a prolonged rivaroxaban half-life [11 to 13 hours]) (Kubitza 2010; Rosencher 2013). The Canadian labeling recommends avoiding doses &gt;10 mg in patients with a postoperative indwelling epidural catheter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9838498\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP2J2 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6754126\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9498&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Rivaroxaban. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<b> Exceptions: </b>Acenocoumarol; Warfarin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Rivaroxaban. Management: In patients with impaired renal function, clarithromycin should not be used unless the potential benefits outweigh the potential risks. This interaction is unlikely clinically significant in patients with normal renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Rivaroxaban. Management: In patients with impaired renal function, erythromycin should not be used unless the potential benefits outweigh the potential risks. This interaction is unlikely clinically significant in patients with normal renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of Rivaroxaban. Management: Consider alternatives to this combination when possible.  Rivaroxaban dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhibitors of CYP3A4 (Moderate) and P-glycoprotein: May increase the serum concentration of Rivaroxaban. Management: No action is needed in patients with normal renal function. US labeling recommends avoidance in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks. Other non-US labels may differ.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Rivaroxaban.<b> Exceptions: </b>Clarithromycin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Rivaroxaban.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Rivaroxaban.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13056049\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724110\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on ex-vivo data, rivaroxaban crosses the placenta (Bapat 2015). Information related to the use of rivaroxaban during pregnancy (Hoeltzenbein 2015) and postpartum (Rudd 2015) is limited. Data are insufficient to evaluate the safety of oral factor Xa inhibitors during pregnancy; use during pregnancy should be avoided (Guyatt 2012). Use may increase the risk of pregnancy related hemorrhage. Clinicians should note that the anticoagulant effect cannot be easily monitored or readily reversed. Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin, hematocrit or blood pressure, or fetal distress. Pregnancy planning should be discussed if use is needed in women of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13940522\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rivaroxaban is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the decision to discontinue rivaroxaban or to discontinue breastfeeding during therapy should take into account the benefits of treatment to the mother; use of alternative anticoagulants is preferred (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724174\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential; renal function prior to initiation, when clinically indicated, and at least annually (AHA/ACC/HRS [January 2014]); hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50929162\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Routine coagulation testing is <b>not</b> required or necessary for DOACs. There are currently no FDA-approved assays or calibration reagents available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. Most commonly used coagulation tests (PT, INR, aPTT) cannot definitively exclude the presence of clinically relevant serum concentrations. A prolonged PT suggests clinically relevant serum concentrations are present, but normal PT and aPTT values using standard reagents cannot rule out the presence of rivaroxaban. Highly sensitive reagents for PT testing may be able to exclude the presence of rivaroxaban. If available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is antifactor Xa activity calibrated specifically for rivaroxaban (undetectable anti-Xa activity likely excludes clinically relevant drug concentrations). An antifactor Xa assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations, but is not useful for quantification (ACC [Tomaselli 2017]; AHA [Raval 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724165\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa) in both the intrinsic and extrinsic coagulation pathways. FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, factor II and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6724145\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: ~50 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~92% to 95% (primarily to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4/5 and CYP2J2</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute bioavailability: 10 mg dose: ~80% to 100%; 20 mg dose: ~66% (fasting; increased with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 5 to 9 hours; Elderly: 11 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (66% primarily via active tubular secretion [~36% as unchanged drug; 30% as inactive metabolites]); feces (28% [7% as unchanged drug; 21% as inactive metabolites])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321848\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Xarelto Starter Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 &amp; 20 mg (51): $854.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Xarelto Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $1,508.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (90): $1,508.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,508.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961940\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ksarelto (UA);</li>\n      <li>Rivarox (BD);</li>\n      <li>RivaXa (BD);</li>\n      <li>Roxarel (BD);</li>\n      <li>Xarelto (AE, AR, AT, AU, BB, BE, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FR, GB, GR, GT, GY, HK, HN, HR, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UY, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27574712\"></a>Abayon M, Kolokythas A, Harrison S, Elad S. Dental management of patients on direct oral anticoagulants: Case series and literature review. <i>Quintessence Int</i>. 2016:47(8):687-696.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/27574712/pubmed\" target=\"_blank\" id=\"27574712\">27574712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abrams PJ and Emerson CR, &ldquo;Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(2):167-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/19170587/pubmed\" target=\"_blank\" id=\"19170587\">19170587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asmis LM, Alberio L, Angelillo-Scherrer A, et al, &ldquo;Rivaroxaban: Quantification by Anti-FXa Assay and Influence on Coagulation Tests: A Study in 9 Swiss Laboratories,&quot; <i>Thromb Res</i>, 2012, 129(4):492-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21840043/pubmed\" target=\"_blank\" id=\"21840043\">21840043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. <i>Am J Obstet Gynecol</i>. 2015;213(5):710.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26164691/pubmed\" target=\"_blank\" id=\"26164691\">26164691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrett YC, Wang Z, Frost C, et al, &ldquo;Clinical Laboratory Measurement of Direct Factor Xa Inhibitors: Anti-Xa Assay is Preferable to Prothrombin Time Assay,&rdquo; <i>Thromb Haemost</i>, 2010, 104(6):1263-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/20978714/pubmed\" target=\"_blank\" id=\"20978714\">20978714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28219692\"></a>Beyer-Westendorf J, Mchellong SM, Gerlach H, et al; SURPRISE investigators. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematol.</i> 2017;4(3):e105-e113. doi: 10.1016/S2352-3026(17)30014-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/28219692/pubmed\" target=\"_blank\" id=\"28219692\">28219692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>J Am Coll Cardiol</i>. 2016;67(24):2888-2899. doi: 10.1016/j.jacc. 2016 .02.082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/27311528/pubmed\" target=\"_blank\" id=\"27311528\">27311528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen AT, Spiro TE, B&uuml;ller HR, et al, &ldquo;Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients,&rdquo; <i>N Engl J Med</i>, 2013, 368(6):513-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/23388003/pubmed\" target=\"_blank\" id=\"23388003\">23388003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crowther MA, Cuker A. Reduced-intensity rivaroxaban for the prevention of recurrent venous thromboembolism. <i>N Engl J Med</i>. 2017;376(13):1279-1280. doi: 10.1056/NEJMe1701628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/28316277/pubmed\" target=\"_blank\" id=\"28316277\">28316277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culebras A, Mess&eacute; SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2014;82(8):716-724. doi: 10.1212/WNL.0000000000000145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/24566225/pubmed\" target=\"_blank\" id=\"24566225\">24566225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Vriese AS, Caluw&eacute; R, Bailleul E, et al. Dose-finding study of rivaroxaban in hemodialysis patients. <i>Am J Kidney Dis</i>. 2015;66(1):91-98. doi: 10.1053/j.ajkd.2015.01.022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/25804678/pubmed\" target=\"_blank\" id=\"25804678\">25804678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. <i>Am J Nephrol</i>. 2016;43(4):229-236. doi: 10.1159/000445328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/27100875/pubmed\" target=\"_blank\" id=\"27100875\">27100875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, &ldquo;Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,&rdquo; <i>Circulation</i>, 2011, 124(14):1573-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21900088/pubmed\" target=\"_blank\" id=\"21900088\">21900088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EINSTEIN CHOICE Investigators, Weitz JI, Lensing AW, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. <i>N Engl J Med</i>. 2017. doi: 10.1056/NEJMoa1700518. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/28316279/pubmed\" target=\"_blank\" id=\"28316279\">28316279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al, &ldquo;Oral Rivaroxaban for Symptomatic Venous Thromboembolism,&rdquo; <i>N Engl J Med</i>, 2010, 363(26):2499-510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21128814/pubmed\" target=\"_blank\" id=\"21128814\">21128814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EINSTEIN-PE Investigators, &ldquo;Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism,&rdquo; <i>New Engl J Med</i>, 2012, 366(14):1287-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22449293/pubmed\" target=\"_blank\" id=\"22449293\">22449293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26386350\"></a>Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. <i>Oral Dis</i>. 2016;22(1):23-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26386350/pubmed\" target=\"_blank\" id=\"26386350\">26386350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eriksson BI, Borris LC, Friedman RJ, et al, &ldquo;Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Hip Arthroplasty,&rdquo; <i>N Engl J Med</i>, 2008, 358(26):2765-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/18579811/pubmed\" target=\"_blank\" id=\"18579811\">18579811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM; European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <i>Eur J Anaesthesiol</i>. 2010;27(12):999-1015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/20890208/pubmed\" target=\"_blank\" id=\"20890208\">20890208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gulseth MP, Michaud J, Nutescu EA, &ldquo;Rivaroxaban: An Oral Direct Inhibitor of Factor Xa,&rdquo; <i>Am J Health Syst Pharm</i>, 2008, 65(16): 1520-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/18693206/pubmed\" target=\"_blank\" id=\"18693206\">18693206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. <i>Clin Res Cardiol</i>. 2015 Jul 21. [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26195125/pubmed\" target=\"_blank\" id=\"26195125\">26195125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. <i>Int J Oral Maxillofac Surg</i>. 2016;45(5):618-630.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kubitza D, Becka M, Mueck W, et al, &ldquo;Effects of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor,&rdquo; <i>Br J Clin Pharmacol</i>, 2010, 70(5):703-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21039764 /pubmed\" target=\"_blank\" id=\"21039764 \">21039764 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kubitza D, Becka M, Voith B, et al, &ldquo;Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939, an Oral, Direct Factor Xa Inhibitor,&rdquo; <i>Clin Pharmacol Ther</i>, 2005, 78(4):412-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/16198660/pubmed\" target=\"_blank\" id=\"16198660\">16198660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kubitza D, Becka M, Wensing G, et al, &ldquo;Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 -- An Oral, Direct Factor Xa Inhibitor -- After Multiple Dosing in Healthy Male Subjects,&rdquo; <i>Eur J Clin Pharmacol</i>, 2005, 61(12):873-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/16328318/pubmed\" target=\"_blank\" id=\"16328318\">16328318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kubitza D, Becka M, Zuehlsdorf M, et al, &ldquo;Body Weight has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects,&rdquo; <i>J Clin Pharmacol</i>, 2007, 47(2):218-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/17244773/pubmed\" target=\"_blank\" id=\"17244773\">17244773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lassen MR, Ageno W, Borris LC, et al, &ldquo;Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty,&rdquo; <i>N Engl J Med</i>, 2008, 358(26):2776-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/18579812/pubmed\" target=\"_blank\" id=\"18579812\">18579812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liakoni E, R&auml;tz Bravo AE, Terracciano L, Heim M, Kr&auml;henb&uuml;hl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. <i>JAMA Intern Med</i>. 2014;174(10):1683-1686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/25155865 /pubmed\" target=\"_blank\" id=\"25155865 \">25155865 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marlu R, Hodaj E, Paris A, et al, &ldquo;Effect of Non-Specific Reversal Agents on Anticoagulant Activity of Dabigatran and Rivaroxaban,&rdquo; <i>Thromb Haemost</i>, 2012, 108(2):217-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22627883/pubmed\" target=\"_blank\" id=\"22627883\">22627883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016; 14(6):1308-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/27299806/pubmed\" target=\"_blank\" id=\"27299806\">27299806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mega JL, Braunwald E, Wiviott SD, et al, &ldquo;Rivaroxaban in Patients With a Recent Acute Coronary Syndrome,&rdquo; <i>N Engl J Med</i>, 2012, 366(1):9-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22077192/pubmed\" target=\"_blank\" id=\"22077192\">22077192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel MR, Hellkamp AS, Lokhnygina Y, et al, &ldquo;Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation,&rdquo; <i>J Am Coll Cardiol</i>, 2013, 61(6):651-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/23391196/pubmed\" target=\"_blank\" id=\"23391196\">23391196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel MR, Mahaffey KW, Garg J, et al, &ldquo;Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation,&rdquo; <i>N Engl J Med</i>, 2011, 365(10):883-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21830957/pubmed\" target=\"_blank\" id=\"21830957\">21830957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2018;49(3):46-110. doi: 10.1161/STR.0000000000000158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/29367334/pubmed\" target=\"_blank\" id=\"29367334\">29367334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in <i>Circulation</i>. 2017;135(10):e647; <i>Circulation</i>. 2017;135(24):e1144]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/28167634/pubmed\" target=\"_blank\" id=\"28167634\">28167634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiol Scand</i>. 2013;57(5):565-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/23336294/pubmed\" target=\"_blank\" id=\"23336294\">23336294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudd KM, Winans AR, Panneerselvam N. Possible Rivaroxaban Failure during the Postpartum Period. <i>Pharmacotherapy</i>. 2015;35(11):e164-168.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/26598101/pubmed\" target=\"_blank\" id=\"26598101\">26598101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25656043\"></a>Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. <i>Odontology</i>. 2015;103(3):258-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/25656043/pubmed\" target=\"_blank\" id=\"25656043\">25656043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2017;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/29203195/pubmed\" target=\"_blank\" id=\"29203195\">29203195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turpie AG, &ldquo;New Oral Anticoagulants in Atrial Fibrillation,&rdquo; <i>Eur Heart J</i>, 2007, 29(2):155-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/18096568/pubmed\" target=\"_blank\" id=\"18096568\">18096568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turpie AG, Lassen MR, Eriksson BI, et al, &ldquo;Rivaroxaban for the Prevention of Venous Thromboembolism After Hip or Knee Arthroplasty. Pooled Analysis of Four Studies,&rdquo; <i>Thromb Haemost</i>, 2011, 105(3):444-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21136019/pubmed\" target=\"_blank\" id=\"21136019\">21136019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. <i>Drug Saf</i>. 2011;34(3):243-252<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/21332248 /pubmed\" target=\"_blank\" id=\"21332248 \">21332248 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wysokinski WE, McBane RD 2nd. Periprocedural bridging management of anticoagulation. <i>Circulation</i>. 2012;126(4):486-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivaroxaban-drug-information/abstract-text/22825410/pubmed\" target=\"_blank\" id=\"22825410\">22825410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xarelto (rivaroxaban) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9498 Version 189.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13135512\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13107816\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6724104\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6724108\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6724168\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6724169\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6724170\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F6724171\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330599\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13107817\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452764\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13376301\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6724172\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6724109\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50324307\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14199109\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6724117\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6724113\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6724114\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9838498\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6754126\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13056049\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6724110\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13940522\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6724174\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50929162\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6724165\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6724145\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321848\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961940\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9498|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rivaroxaban-patient-drug-information\" class=\"drug drug_patient\">Rivaroxaban: Patient drug information \t</a></li></ul></div></div>","javascript":null}